COMPASS Pathways Plc CMPS

Healthcare Biotechnology

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

NDAQ:CMPS - Post by User

COMPASS Pathways Plc

Bullboard Posts

Post by R_J_on Oct 01, 2020 4:52pm

83 Views

Post# 31655136

End of Month - September 2020

End of the Month (EOM) report for September 2020 for COMPASS Pathways Plc.
-
CMPS closed on 09/30/2020 at US$ 34.90
-
S&P 500 Index, @ 3363.0 lost 3.9% in September. [8.1% above its MA(200) @ 3110.0]
-
News Releases on the CMPS Website in September
-
September 22, 2020
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
-
September 18, 2020
COMPASS Pathways announces pricing of upsized initial public offering
-
Who is the Big Cheese at CMPS?
George Goldsmith, Chairman, Chief Executive Officer, and Co founder
Lars Christian Wilde, President, Chief Business Officer, and Co founder
-
RJ

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features